Table 2.
Five‐year rates of recurrence in patients with stage I adenocarcinoma according to the immunohistochemical staining scores of intravascular tumors
| No. of patients | 5‐year PR, % | P‐value† | |
|---|---|---|---|
| Cancer phenotype | |||
| E‐cadherin | |||
| High | 20 | 55.0 | |
| Low | 21 | 9.5 | 0.004* |
| CD44 | |||
| High | 19 | 42.1 | |
| Low | 22 | 22.7 | 0.410 |
| CD44 variant 6 | |||
| High | 20 | 25.0 | |
| Low | 21 | 38.1 | 0.229 |
| Vimentin | |||
| High | 22 | 36.4 | |
| Low | 19 | 26.3 | 0.846 |
| Stromal phenotype | |||
| CD204 | |||
| High | 20 | 50.0 | |
| Low | 21 | 14.3 | 0.016* |
| CD34 | |||
| High | 22 | 50.0 | |
| Low | 19 | 10.5 | 0.007* |
| α‐SMA | |||
| High | 19 | 47.4 | |
| Low | 22 | 18.2 | 0.033* |
*Significant. †Log–rank test. α‐SMA, α‐smooth muscle actin; High, greater than the median; Low, less than or equal to the median; PR, proportion of recurrence.